These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 8063247)

  • 1. p53 alterations in uterine leiomyosarcomas versus leiomyomas.
    de Vos S; Wilczynski SP; Fleischhacker M; Koeffler P
    Gynecol Oncol; 1994 Aug; 54(2):205-8. PubMed ID: 8063247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus.
    Jeffers MD; Farquharson MA; Richmond JA; McNicol AM
    J Pathol; 1995 Sep; 177(1):65-70. PubMed ID: 7472782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas.
    Rao UN; Finkelstein SD; Jones MW
    Mod Pathol; 1999 Nov; 12(11):1001-9. PubMed ID: 10574596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis.
    Hsueh C; Wang H; Gonzalez-Crussi F; Lin JN; Hung IJ; Yang CP; Jiang TH
    Mod Pathol; 2002 Jun; 15(6):606-10. PubMed ID: 12065773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.
    Liu FS; Kohler MF; Marks JR; Bast RC; Boyd J; Berchuck A
    Obstet Gynecol; 1994 Jan; 83(1):118-24. PubMed ID: 8272291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of the c-myc proto-oncogene occurs frequently in uterine sarcomas.
    Jeffers MD; Richmond JA; Macaulay EM
    Mod Pathol; 1995 Sep; 8(7):701-4. PubMed ID: 8539225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation analysis of CDP, TP53, and KRAS in uterine leiomyomas.
    Patrikis MI; Bryan EJ; Thomas NA; Rice GE; Quinn MA; Baker MS; Campbell IG
    Mol Carcinog; 2003 Jun; 37(2):61-4. PubMed ID: 12766905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas.
    Hall KL; Teneriello MG; Taylor RR; Lemon S; Ebina M; Linnoila RI; Norris JH; Park RC; Birrer MJ
    Gynecol Oncol; 1997 May; 65(2):330-5. PubMed ID: 9159347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations of p53 gene in gastric carcinoma in Taiwan.
    Wang JY; Lin SR; Hsieh JS; Hsu CH; Huang YS; Huang TJ
    Anticancer Res; 2001; 21(1B):513-20. PubMed ID: 11299797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors.
    Schwetye KE; Pfeifer JD; Duncavage EJ
    Hum Pathol; 2014 Jan; 45(1):65-70. PubMed ID: 24196187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 mutational spectrum of esophageal carcinomas from five different geographical locales in China.
    Lung ML; Chan WC; Zong YS; Tang CM; Fok CL; Wong KT; Chan LK; Lau KW
    Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):277-84. PubMed ID: 8722219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling.
    Quade BJ; Wang TY; Sornberger K; Dal Cin P; Mutter GL; Morton CC
    Genes Chromosomes Cancer; 2004 Jun; 40(2):97-108. PubMed ID: 15101043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism of the p53 tumor suppressor gene is associated with susceptibility to uterine leiomyoma.
    Denschlag D; Bettendorf H; Watermann D; Keck C; Tempfer C; Pietrowski D
    Fertil Steril; 2005 Jul; 84(1):162-6. PubMed ID: 16009172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
    Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
    Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of the p53 gene in human functional adrenal neoplasms.
    Lin SR; Lee YJ; Tsai JH
    J Clin Endocrinol Metab; 1994 Feb; 78(2):483-91. PubMed ID: 8106638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
    Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
    J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus.
    Zhai YL; Nikaido T; Toki T; Shiozawa A; Orii A; Fujii S
    Br J Cancer; 1999 Jul; 80(10):1658-64. PubMed ID: 10408415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
    Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE
    Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 alterations in chemically induced hamster cheek-pouch lesions.
    Gimenez-Conti IB; LaBate M; Liu F; Osterndorff E
    Mol Carcinog; 1996 Aug; 16(4):197-202. PubMed ID: 8784462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.